Theratechnologies (TSE:TH) has released an update.
Theratechnologies Inc. has advanced to a higher dose level in their ongoing Phase 1 clinical trial for sudocetaxel zendusortide, targeting advanced ovarian cancer, with the first patient already treated under the new protocol. This follows the Medical Review Committee’s approval, finding the previous dosage safe, and marks a significant step towards addressing the high unmet medical need in platinum-resistant ovarian cancer patients. The company’s SORT1+ Technology platform underpins the novel peptide-drug conjugate, which has received Fast Track designation from the FDA for treating sortilin-positive advanced solid tumors.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
